The Asian Cervical Cancer Screening Market is expected to grow rapidly with a CAGR of 3.79% by 2028

Cervical cancer is a serious global health concern because it has the seventh highest rate of all cancers. There are 1786,49 million women in Asia who are 15 years of age or older and who are highly susceptible to developing cervical cancer. The HPV Information Center estimates that 351,720 women are diagnosed with cervical cancer each year, and 199,902 of them pass away as a result of the disease. Women in Asia are more likely than anyone else to develop cervical cancer.
The changes brought on by precancerous or cancerous in the cervix can be identified with the aid of cervical cancer screening. Routine Pap testing has been recommended for women over 30 but clinical recommendations and risk factors are changing. Precancerous changes must be identified to be treated.
Early diagnostic procedures like colposcopy and pelvic exams should be performed due to the high risk of rising cervical cancer cases so that doctors can gain a clear understanding of the tissues. For women, the most pertinent and early tests can be Pap and HPV tests. These facilities will increasingly employ some of the most cutting-edge techniques for cervical cancer diagnosis, which will accelerate the market's expansion.
The Indian government has spearheaded numerous initiatives for cervical cancer prevention, such as spreading awareness of early detection, and there is a need for strong R&D on cervical cancer diagnosis and drugs from major players. Gynecologists and nurses are properly guided and educated about this cause to identify it. Additionally, these programs help the market grow. More effective test-medication combinations are anticipated to be developed, which will lead to a successful market expansion.